0001493152-26-023750
SEC filingNarrowed operating and net losses through lower costs and expenses versus prior year, driven by reduced clinical charges including non-core patent costs, though cash used in operations rose due to accounts payable paydown amid ongoing funding needs.
Revenue rose 37.5% to $22 thousand in Q1 FY2026 from $16 thousand in the prior-year quarter, stemming from US clinical treatment programs including the AMP-511 Expanded Access Program for ME/CFS and Post-COVID conditions. This uptick remains immaterial relative to the company's development-stage focus on Ampligen for immuno-oncology and antiviral applications, where preclinical data supports broad-spectrum potential and recent immune marker improvements (e.g., CD8a/CD4 ratio, p=0.03) were noted in trials.
Net cash used by operating activities rose to -$2.7 million from -$2.4 million, primarily due to cash utilization for accounts payable as explained in MD&A. Ongoing operating losses combined with limited working capital raise substantial doubt about going concern status for at least one year post-issuance. Management is committed to a focused plan seeking senior co-development partners to fund commercialization of Ampligen's therapeutic aspects and Alferon, while additional funding will be needed for operations and studies, especially if trials require changes.